299
Participants
Start Date
June 30, 2015
Primary Completion Date
February 29, 2016
Study Completion Date
February 29, 2016
Bococizumab 150mg
Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
Bococizumab 75mg
Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
Bococizumab 150mg placebo
Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
Bococizumab 75mg placebo
Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
Manassas Clinical Research Center, Manassas
National Clinical Research-Richmond, Inc., Richmond
Heart Care Associates, P.C., Hopewell
PharmQuest, Greensboro
PMG Research Of Charleston, Mt. Pleasant
Palmetto Clinical Research, Summerville
North Georgia Clinical Research, Woodstock
North Georgia Internal Medicine, Woodstock
Clinical Research Atlanta, Stockbridge
A & R Research Group LLC, Pembroke Pines
Clinical Research of Miami, Inc., Miami
Prestige Clinical Research Center, Inc., Miami
Clinical Research of South Florida, Coral Gables
Invesclinic, LLC, Fort Lauderdale
ACRC - Cardiology, Atlantis
L-MARC Research Center, Louisville
Sterling Research Group, Ltd., Cincinnati
Midwest Institute For Clinical Research, Indianapolis
Buynak Clinical Research, P.C., Valparaiso
Evanston Premier Healthcare Research,LLC, Evanston
Omega Clinical Research Center, Metairie
Texas Center for Drug Development, Inc., Houston
Solaris Clinical Research, Meridian
Radiant Research Incorporated, Chandler
National Research Institute, Los Angeles
California Medical Research Associates Inc., Northridge
Diablo Clinical Research, Inc., Walnut Creek
Clinical Trial Research, Lincoln
Northern California Research, Sacramento
Rainier Clinical Research Center, Inc., Renton
Lead Sponsor
Pfizer
INDUSTRY